Lake Street upgraded Inotiv to Buy from Hold with a price target of $4, up from $2. The firm, which had previously downgraded shares on balance sheet concerns and a
Lake Street upgraded Inotiv to Buy from Hold with a price target of $4, up from $2. The firm, which had previously downgraded shares on balance sheet concerns and a
An update from Inotiv ( ($NOTV) ) is now available. Inotiv, Inc. has taken strategic financial steps by amending its Credit Agreement and issuing $22.6 million of 15% Senior Secured
Lake Street analyst Frank Takkinen maintained a Hold rating on Inotiv (NOTV – Research Report) today and set a price target of $2.00. The company’s shares opened today at $1.60.
Inotiv has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount of 15% Senior Secured Second Lien PIK Notes
WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) — Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement.